問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Digestive System Department

更新時間:2023-09-19

周仁偉Chou, Jen-Wei
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月
  • codecol@yahoo.com.tw

篩選

List

68Cases

2025-08-01 - 2030-04-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-01-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-07-01 - 2027-11-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2016-10-10 - 2022-08-31

Phase III

Active
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis
  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
8Sites

Recruiting3Sites

Terminated3Sites

2022-02-01 - 2023-09-21

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-09-15 - 2024-01-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-01-01 - 2025-06-30

Phase III

Active
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 OA investigational vaccine

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2024-06-01 - 2025-03-28

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-07-01 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites